Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03220958 · ClinicalTrials.gov registry record · Phase 3

Metoclopramide for Post Traumatic Headache

A Phase 3 study of Post-Traumatic Headache, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 3
Development phase
160
Enrollment target
1
Study location

NCT03220958 is a Phase 3 study of Post-Traumatic Headache that has completed, run by Montefiore Medical Center. The registered enrollment target is 160 participants, above the 81-participant average among 8 other Post-Traumatic Headache trials with a reported enrollment target (98% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03220958, a Phase 3 study of Post-Traumatic Headache, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

Nearly 1.5 million patients present to US emergency departments annually following head trauma. Headache is a frequent symptom of victims of head trauma. The purpose of this study is to see if an intravenous medication called metoclopramide can improve the symptoms of patients with acute post-traumatic headache.

Conditions Studied

Interventions

  • DRUG Normal saline
  • DRUG Diphenhydramine
  • DRUG Metoclopramide

Study Locations (1)

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2017-08-01
Est. Completion 2020-04-01
Phase Phase 3

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT03220958

The ClinicalTrials.gov registry entry for NCT03220958 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 8 other Post-Traumatic Headache trials with a reported enrollment target (98% higher). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post-Traumatic Headache appearing as the primary indexed condition, and to 3 interventions - of which Normal saline is the first listed.

NCT03220958 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03220958 about?

NCT03220958 is a clinical study titled "Metoclopramide for Post Traumatic Headache". Nearly 1.5 million patients present to US emergency departments annually following head trauma. Headache is a frequent symptom of victims of head trauma. The purpose of this study is to see if an intravenous medication called metoclopramide can improve the symptoms of patients with acute post-trauma...

What is the current status of trial NCT03220958?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2017-08-01. Estimated completion is 2020-04-01.

What conditions does trial NCT03220958 study?

This clinical trial studies the following conditions: Post-Traumatic Headache.

What interventions are being tested in trial NCT03220958?

The interventions under investigation include: Normal saline (DRUG), Diphenhydramine (DRUG), Metoclopramide (DRUG).

Who is sponsoring clinical trial NCT03220958?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03220958 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Traumatic Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.